DelveInsight’s, “Thyroid Cancer Pipeline Insight 2026” report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Thyroid Cancer pipeline landscape. It covers the Thyroid Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Thyroid Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Download DelveInsight’s comprehensive Thyroid Cancer Pipeline Report to explore emerging therapies @ Thyroid Cancer Pipeline Outlook Report
Key Takeaways from the Thyroid Cancer Pipeline Report
- On March 25, 2026, Hoffmann-La Roche initiated a Phase 1/2 multicenter dose escalation study in pediatric patients with relapsed or refractory extracranial solid tumors (Phase 1), with additional expansion cohorts (Phase 2) in patients with primary brain tumors harboring NTRK1/2/3 or ROS1 gene fusions, and extracranial solid tumors harboring NTRK1/2/3 or ROS1 gene fusions.
- On March 24, 2026, Xintian Pharmaceutical conducted a study was the rate of change in thyroid nodule volume from baseline at 9 months of treatment. The rate of change in thyroid nodule volume from baseline at 3 and 6 months of treatment was a secondary efficacy endpoint. Other secondary efficacy endpoints included maximum thyroid nodule diameter, number of thyroid nodules, proportion of patients with reduced thyroid nodule volume or ≥50% from baseline, thyroid volume, thyroid function (serum TSH, FT3, FT4, thyroid egg levels (Tg), thyroid antibody levels (TgAb, TPOAb), quality of life evaluation (SF-36), etc. Safety endpoints included incidence of AE/ serious adverse events (SAE), causality, and outcomes. Incidence of AE/SAE leading to discontinuation. Changes in safety laboratory test values from baseline.
- On March 19, 2026, Loxo Oncology Inc. announced a phase 3 study is to see if the study drug selpercatinib is safe and more effective compared to a standard treatment in participants with rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) that cannot be removed by surgery or has spread to other parts of the body. Participants who are assigned to the standard treatment and discontinue due to progressive disease have the option to potentially crossover to selpercatinib.
- DelveInsight’s Thyroid Cancer pipeline report depicts a robust space with 45+ active players working to develop 50+ pipeline therapies for Thyroid Cancer treatment.
- The leading Thyroid Cancer Companies such as Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Genentech, Sichuan Kelun-Biotech Biopharmaceutical, AffyImmune Therapeutics, Bayer, Gilead Sciences, Model Medicines, Biovista, Xynomic Pharmaceuticals, TYK Medicines, Solve Therapeutics, Pfizer, Fore Biotherapeutics, Beijing Scitech-Mq Pharmaceuticals Limited, Sunshine Lake Pharma Co., Ltd. and others.
- Promising Thyroid Cancer Therapies such as Selpercatinib, Cabozantinib, Vandetanib, E7080 Capsule, Lenvatinib (DTC Cohort), Irofulven + capecitabine, XL184, AL2846 Capsule, and others.
Access DelveInsight’s in-depth Thyroid Cancer Pipeline Analysis for a closer look at promising breakthroughs @ Thyroid Cancer Clinical Trials and Studies
The Thyroid Cancer Pipeline Report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Thyroid Cancer Pipeline Report also highlights the unmet needs with respect to the Thyroid Cancer.
Thyroid Cancer Overview
Thyroid cancer is a malignant condition that primarily arises from the follicular cells of the thyroid gland, which are responsible for producing thyroid hormones. The symptoms of thyroid cancer include a neck lump, hoarseness, difficulty swallowing, and swollen lymph nodes, though many early cases are asymptomatic. Thyroid cancer risk is influenced by a combination of genetic, environmental, and lifestyle factors. The most well-established cause is exposure to ionizing radiation, particularly during childhood, which significantly raises the likelihood of developing thyroid malignancies. Inherited genetic syndromes such as MEN2, Cowden syndrome, and familial medullary thyroid cancer also contribute to increased risk. Women are more commonly affected, possibly due to hormonal influences like estrogen. Lifestyle and environmental factors, including obesity, low iodine intake, and exposure to pollutants, may also play a key role.
Thyroid Cancer Emerging Drugs Profile
- AL2846: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
AL-2846 is an investigational small-molecule kinase inhibitor developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. It targets receptor protein-tyrosine kinases, aiming to block cancer cell growth. The current trials are focused on its use in iodine-refractory differentiated thyroid cancer (both alone and in combination with other therapies), neurofibromatosis type 1 (NF1), and pancreatic cancer. The drug is being evaluated under Phase III stage of its clinical trial for the treatment of Thyroid Cancer.
- Vemurafenib: Genentech
Vemurafenib (Zelboraf) is an oral, small molecule, BRAF kinase inhibitor. The BRAF protein is a key component of the RAS-RAF pathway involved in normal cell growth and survival. Mutations that keep the BRAF protein in an active state may cause excessive pathway signalling, leading to uncontrolled cell growth and survival. Vemurafenib is designed to block the BRAF gene mutation. By blocking this mutation, the drug may kill the cancer cells with the mutation and/or stop the tumor from growing. The drug is currently in Phase II stage of its clinical trial for the treatment of Thyroid Cancer.
- A400: Sichuan Kelun-Biotech Biopharmaceutical
A400/EP0031 (KL590586 Capsules) is a new generation of selective RET small molecule kinase inhibitor (SRI) with extensive activity against RET gene fusion and mutations, and has the potential to overcome first-generation SRI resistance. In preclinical studies, A400/EP0031 showed good inhibitory activity against RET kinase in vitro and in vivo, and also demonstrated good blood-brain barrier penetration in animal models. Ellipses, a UK based international drug development company, was granted an exclusive license to develop, manufacture and commercialize A400 outside Greater China and certain Asian countries. The drug is currently being evaluated under Phase I/II stage of its clinical trial for the treatment of Thyroid Cancer.
- AIC100: AffyImmune Therapeutics
AIC100 is an affinity‑tuned, third‑generation CAR‑T cell therapy engineered to target ICAM‑1 on advanced thyroid cancers, including anaplastic (ATC) and poorly differentiated (PDTC) types. ICAM-1, found on the surface of cancer cells, acts as a binding site for LFA-1 on AIC100 CAR T cells, facilitating their recognition and destruction of malignant cells. AffyImmune has chosen anaplastic and advanced differentiated thyroid cancers as the initial indication for AIC100 and has received Orphan Drug, Fast Track, and Regenerative Medicine Advanced Therapy Designations from the FDA. The drug is currently in Phase I stage of its clinical trial for the treatment of Thyroid Cancer.
Get a detailed analysis of the latest innovations in the Thyroid Cancer pipeline @ Thyroid Cancer Unmet Needs
The Thyroid Cancer pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Thyroid Cancer with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Thyroid Cancer Treatment.
- Thyroid Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Thyroid Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Thyroid Cancer market.
Thyroid Cancer Companies
AffyImmune Therapeutics, Suzhou Zelgen Biopharmaceuticals, Bristol-Myers Squibb, Suzhou NeuPharma, AstraZeneca, Verastem Oncology, Thryv Therapeutics, Molecular Targeting Technologies, Chimerix, Codiak BioSciences, LeadArtis, Tyra Biosciences, Roche, Sichuan Kelun-Biotech Biopharmaceutical, Advenchen Laboratories, and others.
Thyroid Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Thyroid Cancer Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Download DelveInsight’s latest report to gain strategic insights into upcoming Thyroid Cancer Therapies @ Thyroid Cancer Market Drivers and Barriers, and Future Perspectives
Scope of the Thyroid Cancer Pipeline Report
- Coverage- Global
- Thyroid Cancer Companies- AffyImmune Therapeutics, Suzhou Zelgen Biopharmaceuticals, Bristol-Myers Squibb, Suzhou NeuPharma, AstraZeneca, Verastem Oncology, Thryv Therapeutics, Molecular Targeting Technologies, Chimerix, Codiak BioSciences, LeadArtis, Tyra Biosciences, Roche, Sichuan Kelun-Biotech Biopharmaceutical, Advenchen Laboratories, and others.
- Thyroid Cancer Therapies- Selpercatinib, Cabozantinib, Vandetanib, E7080 Capsule, Lenvatinib (DTC Cohort), Irofulven + capecitabine, XL184, AL2846 Capsule, and others.
- Thyroid Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Thyroid Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Thyroid Cancer drug development? @ Thyroid Cancer Emerging Drugs and Major Companies
Table of Content
- Introduction
- Executive Summary
- Thyroid Cancer: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Thyroid Cancer– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- rhTSH: Suzhou Zelgen Biopharmaceuticals
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Nivolumab: Bristol-Myers Squibb
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- AIC100:Affyimmune Therapeutics
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Thyroid Cancer Key Companies
- Thyroid Cancer Key Products
- Thyroid Cancer- Unmet Needs
- Thyroid Cancer- Market Drivers and Barriers
- Thyroid Cancer- Future Perspectives and Conclusion
- Thyroid Cancer Analyst Views
- Thyroid Cancer Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/